FDA approves FET-PET agent for glioma - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves FET-PET agent for glioma

The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.

  • By

  • Kathryn Wighton

  • September 14, 2026

  • 2 min

Share

  • 1

    The FDA approved floretyrosine F 18 (Pixclara) for PET imaging to differentiate glioma from treatment-related changes.

  • 2

    Floretyrosine F 18 is the first FDA-approved FET-PET imaging drug for glioma, applicable to patients aged 1 month or older.

  • 3

    Approximately 24,000 new glioma cases are diagnosed annually in the US, highlighting the need for effective imaging.

  • 4

    The safety evaluation of floretyrosine F 18 included 382 patients, with minimal adverse effects reported.

  • 5

    PET results from floretyrosine F 18 should be interpreted alongside other clinical information to avoid misinterpretation.

Original Source(s)

FDA approves FET-PET agent for glioma

  • by Kathryn Wighton

  • September 14, 2026

Related Content

Oversight May Be Critical in Patient Acceptance of AI in Radiology

A UK survey found that patients supported AI as a clinical tool but wanted physicians to remain responsible for medical decisions.

Use of HIFU for Tremor-Dominant Parkinson’s Disease: A Patient Success Story

HIFU is an FDA-approved procedure that uses highly focused ultrasound waves to target a small area in the brain’s thalamus responsible for tremors.

  • April 17, 2026

  • 7 min
No Short-Term Brain Changes in Youth Soccer

Researchers tracked cognitive, behavioral, imaging, and biomarker outcomes in 129 adolescent athletes across one season.